David Steensma: IND application for first type II JAK2 inhibitor to go into clinical trials
David Steensma, Chief Medical Officer at Ajax Therapeutics, shared a post by Ajax Therapeutics on X/Twitter:
“We’ve been busy at Ajax Therapeutics! IND application for first type II JAK2 inhibitor (AJ1-11095) to go into clinical trials, based on pre-clinical work done at Ross Levine lab and with a molecule designed in collaboration with Schrödinger Therapeutics, has been cleared by U.S. FDA.
Here’s the listing for the first-in-human AJ1-11095 study (NCT06343805) for patients with myelofibrosis who’ve previously been treated with a type I JAK2 inhibitor but still have symptoms and an enlarged spleen.”
Quoting Ajax Therapeutics’s post:
“Ajax Announcement #2. The IND for our lead molecule, AJ-101095, a potent selective type II JAK inhibitor, has been cleared by the FDA. Next stop->clinic. Let’s go!.”
Source: David Steensma/X and Ajax Therapeutics/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023